Morgan Stanley sees Eli Lilly shares rallying on data showing heart benefit of Novo’s obesity drug

Danish drugmaker Novo Nordisk's promising data on its obesity drug Wegovy should spill over to also benefit Eli Lilly, a Wall Street bank says. Originally published at CNBC